Skip to content
Studies have shown that active fund managers routinely underperform the S&P500 index*
Home
Articles
WALL STREET X
Forecasts
Portfolios
Wall Street X
Articles
Forecasts
Portfolios
Search
Results for
{phrase}
(
{results_count}
of
{results_count_total}
)
Displaying
{results_count}
results of
{results_count_total}
Maze Therapeutics, Inc. (NASDAQ: MAZE)
MAZE Stock Predictions and Ratings
WSX Rating:
STRONG SELL
WSX Forecast (1yr):
-17.90%
Analyst Rating:
STRONG BUY
Analyst Forecast (1yr):
145.90%
MAZE Stock Analysis
MAZE
PE Ratio:
MAZE
PEG Ratio:
Not Available
MAZE
Forward EPS Growth (12 month):
0.00%
MAZE
PS Ratio:
68.8
MAZE
PSG Ratio:
Not Available
MAZE
Forward Revenue Growth (12 month):
0.00%
MAZE Articles
No data was found